-
131.
公开(公告)号:US20150231255A1
公开(公告)日:2015-08-20
申请号:US14408423
申请日:2013-06-18
Applicant: HISAMITSU PHARMACEUTICAL CO., INC.
Inventor: Takaaki Yoshinaga , Masahiro Sato , Akira Oishi , Yasuhisa Kose
IPC: A61K47/30 , A61K31/196 , A61K47/10 , A61K9/70
CPC classification number: A61K47/30 , A61K9/7053 , A61K9/7069 , A61K31/196 , A61K47/06 , A61K47/10 , A61K47/34 , A61K47/46
Abstract: A transdermal absorption promoting agent for promoting percutaneous absorption of diclofenac sodium, comprising 1-menthyl glyceryl ether, a petroleum-based resin and/or a terpene-based resin, as well as a patch comprising it.
Abstract translation: 一种用于促进双氯芬酸钠的经皮吸收的透皮吸收促进剂,其包含1-薄荷基甘油醚,石油基树脂和/或萜烯系树脂,以及包含它的贴剂。
-
公开(公告)号:US20140322300A1
公开(公告)日:2014-10-30
申请号:US14363559
申请日:2012-12-06
Applicant: Hisamitsu Pharmaceutical Co., Inc.
Inventor: Masaru Kijima , Yasuhisa Kose , Takaaki Yoshinaga
IPC: A61K31/196 , A61K47/10 , A61K47/02 , A61K9/70
CPC classification number: A61K9/7061 , A61K9/7069 , A61K31/196 , A61K47/02 , A61K47/10
Abstract: A patch comprising a support layer and an adhesive agent layer, wherein the adhesive agent layer contains diclofenac or a pharmaceutically acceptable salt thereof, glycerin, butylene glycol, and poly(ethylene glycol)monooleate, and a mass ratio between the butylene glycol and the poly(ethylene glycol)monooleate (mass of butylene glycol:mass of poly(ethylene glycol)monooleate) is 1:1 to 4:1.
Abstract translation: 一种贴剂,包括支持层和粘合剂层,其中所述粘合剂层包含双氯芬酸或其药学上可接受的盐,甘油,丁二醇和聚(乙二醇)单油酸酯,并且所述丁二醇和聚 (乙二醇)单油酸酯(丁二醇的质量:聚(乙二醇)单油酸酯的质量)为1:1至4:1。
-
公开(公告)号:US20250082591A1
公开(公告)日:2025-03-13
申请号:US18960714
申请日:2024-11-26
Applicant: HISAMITSU PHARMACEUTICAL CO., INC.
Inventor: Kentaro NAKASHIMA , Yusuke TANAKA , Keiichiro TSURUSHIMA
IPC: A61K31/167 , A61K9/70 , A61K47/10
Abstract: Disclosed is a patch comprising an adhesive layer on a backing layer, wherein the adhesive layer comprises lidocaine or a pharmaceutically acceptable salt thereof, propylene glycol, a rubber adhesive base and a terpene resin, wherein the content of the lidocaine or pharmaceutically acceptable salt thereof in the adhesive layer is 3 mass % to 5 mass % with respect to the total mass of the adhesive layer, the content of the terpene resin in the adhesive layer is 5 mass % to 18 mass % with respect to the total mass of the adhesive layer, and the content of propylene glycol in the adhesive layer is 3 mass % to 7 mass % with respect to the total mass of the adhesive layer, wherein crystals are not precipitated in the patch, and wherein the adhesive layer has an adhesive surface, and requires a force of 1.3 N or less to release the adhesive surfaces during self-adhesion.
-
公开(公告)号:US12178922B2
公开(公告)日:2024-12-31
申请号:US17244552
申请日:2021-04-29
Applicant: HISAMITSU PHARMACEUTICAL CO., INC.
Inventor: Ryo Tanaka , Hideaki Ohashi , Naruhide Miyoshi , Takito Shima , Naoko Fujita , Yasunari Michinaka
IPC: A61K9/70 , A61K31/192 , A61K31/196 , A61K31/405 , A61K47/12 , A61K47/20 , A61K47/32
Abstract: The patch of the present invention comprises a backing layer and an adhesive layer laminated on the backing layer, wherein a water vapor transmission rate of the backing layer is 400 g/m2·24 hours or more, and the adhesive layer comprises a drug, dimethylsulfoxide and an adhesive. Such a patch does not fall off easily even after long wear.
-
公开(公告)号:US20240342125A1
公开(公告)日:2024-10-17
申请号:US18683376
申请日:2022-09-21
Applicant: HISAMITSU PHARMACEUTICAL CO., INC.
Inventor: Naoko FUJITA , Nao IWAMOTO , Kazuyuki HIROSE , Naoyuki UCHIDA
IPC: A61K31/196 , A61K9/70
CPC classification number: A61K31/196 , A61K9/7061 , A61K9/7069
Abstract: A method for inhibiting the generation of diclofenac indolinones in an adhesive patch is provided. This adhesive patch comprises a support body layer and an adhesive layer that is layered on the support body layer. The aforementioned method includes a step for mixing a diclofenac free acid and an adhesive base to acquire an adhesive composition, and a step for shaping the adhesive composition to obtain an adhesive patch. The content of the diclofenac free acid is 0.5-8 mass % on the basis of the total mass of the adhesive layer.
-
公开(公告)号:US20240122898A1
公开(公告)日:2024-04-18
申请号:US17768555
申请日:2020-10-19
Applicant: HISAMITSU PHARMACEUTICAL CO., INC.
Inventor: Yuka TAKAGI , Masaki YUKUHIRO
IPC: A61K31/407 , A61K9/70 , A61K47/02
CPC classification number: A61K31/407 , A61K9/7053 , A61K47/02
Abstract: The present invention provides a patch comprising an adhesive layer on a backing, the adhesive layer comprising: asenapine or a pharmaceutically acceptable salt thereof; an adhesive base; and at least one selected from the group consisting of thiosulfates, sulfites, and pyrosulfites.
-
公开(公告)号:USD1014284S1
公开(公告)日:2024-02-13
申请号:US29723539
申请日:2020-02-07
Applicant: HISAMITSU PHARMACEUTICAL CO., INC.
Designer: Michiaki Tsuji , Hiroyuki Nagashima
Abstract: FIG. 1 is a front perspective view of a spray container.
FIG. 2 is a rear perspective view thereof.
FIG. 3 is a front view thereof.
FIG. 4 is a rear view thereof.
FIG. 5 is a top plan view thereof.
FIG. 6 is a bottom plan view thereof.
FIG. 7 is a right side view thereof.
FIG. 8 is a left side view thereof.
FIG. 9 is an enlarged sectional view taken along the line 9-9 in FIG. 5 with the unclaimed bottle portion partially removed for ease of illustration.
FIG. 10 is a reference front perspective view showing the unlocked state thereof; and,
FIG. 11 is a reference rear perspective view showing the unlocked state thereof.
The broken lines show portions of a spray container that form no part of the claimed design.
The alternate long and short dash lines are merely the boundary lines between the claimed portions and the non-claimed portions.-
公开(公告)号:US20230414530A1
公开(公告)日:2023-12-28
申请号:US18035951
申请日:2021-11-08
Applicant: HISAMITSU PHARMACEUTICAL CO., INC.
Inventor: Yuka TAKAGI , Nao IWAMOTO
IPC: A61K9/70 , A61K47/18 , A61K31/407
CPC classification number: A61K9/7046 , A61K47/18 , A61K31/407
Abstract: Disclosed is a method for inhibiting degradation of asenapine or a pharmaceutically acceptable salt thereof in a patch. The patch comprises an adhesive layer on a base, and the adhesive layer contains an adhesive base and asenapine or a pharmaceutically acceptable salt thereof. The method includes incorporating at least one amine compound selected from the group consisting of monoethanolamine, diethanolamine, diisopropanolamine, isopropanolamine, triethanolamine and meglumine in the adhesive layer.
-
公开(公告)号:US20230346720A1
公开(公告)日:2023-11-02
申请号:US18083793
申请日:2022-12-19
Applicant: HISAMITSU PHARMACEUTICAL CO., INC.
Inventor: Kentaro NAKASHIMA , Yusuke TANAKA , Keiichiro TSURUSHIMA
IPC: A61K9/70 , A61K31/167 , A61K47/10
CPC classification number: A61K31/167 , A61K9/7046 , A61K47/10
Abstract: Disclosed is a patch comprising an adhesive layer on a backing layer, wherein the adhesive layer comprises lidocaine or a pharmaceutically acceptable salt thereof, propylene glycol, a rubber adhesive base and a terpene resin, wherein the content of the lidocaine or a pharmaceutically acceptable salt thereof in the adhesive layer in terms of free form is 2 mass% to 6 mass% with respect to the total mass of the adhesive layer, wherein the ratio of the mass of the lidocaine or a pharmaceutically acceptable salt thereof in terms of free form to the mass of propylene glycol in the adhesive layer is 1:0.6 to 1:1.8, and wherein the content of the terpene resin in the adhesive layer is 5 mass% to 18 mass% with respect to a total mass of the adhesive layer.
-
公开(公告)号:US20230310340A1
公开(公告)日:2023-10-05
申请号:US18036203
申请日:2021-11-08
Applicant: HISAMITSU PHARMACEUTICAL CO., INC.
Inventor: Yuka TAKAGI , Nao IWAMOTO
IPC: A61K9/70 , A61K31/407 , A61K47/18
CPC classification number: A61K9/7069 , A61K31/407 , A61K47/183
Abstract: Disclosed is a patch in which degradation of asenapine or a pharmaceutically acceptable salt thereof is inhibited. The patch comprises an adhesive layer on a base, wherein the adhesive layer contains an adhesive base, asenapine or a pharmaceutically acceptable salt thereof, and at least one basic amino acid selected from the group consisting of lysine, arginine and histidine, or a pharmaceutically acceptable salt of said basic amino acid.
-
-
-
-
-
-
-
-
-